Double Bond Pharmaceutical International ABNGM: DBP.B

DBP.B: SI-053 clinical progress and new partnerships drive Double Bond Pharmaceutical's strategic focus

· Issued by Double Bond Pharmaceutical International AB

Double Bond Pharmaceutical reported lower revenues and continued losses in H1 2024, but advanced SI-053 development and secured new financing and partnerships, including a key deal with Vivo Biopharma.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Double Bond Pharmaceutical International AB on 6ix

Later from Double Bond Pharmaceutical International

All Double Bond Pharmaceutical International news releases